Embecta

Embecta Net Change in Cash

The Net Change in Cash of Embecta (EMBC) as of Nov 11, 2026 is -45.60 M USD. In the previous year, Net Change in Cash was -52.30 M USD — a change of -12.81% (higher).

Net Change in Cash

-45.60 MUSD

YoY

-12.81%

Last updated:

Net Change in Cash of Embecta is 2025 -45.60 M USD. Net Change in Cash of Embecta was 2024 -52.30 M USD. It decreases by -12.81% higher compared to the previous year.

The Embecta Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2019
-436.00 M USD
Jan 1, 2020
-457.00 M USD
Jan 1, 2021
-417.00 M USD
Jan 1, 2022
330.90 M USD
Jan 1, 2023
-4.40 M USD
Jan 1, 2024
-52.30 M USD
Jan 1, 2025
-45.60 M USD
The Embecta Net Change in Cash history
YEARNet Change in CashYoY
-45.60 MUSD-12.81%
-52.30 MUSD+1,088.64%
-4.40 MUSD-101.33%
330.90 MUSD-179.35%
-417.00 MUSD-8.75%
-457.00 MUSD+4.82%
-436.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Net Change in Cash of Embecta is -45.60 M USD in 2025.

Net Change in Cash of Embecta changed from -52.30 M USD to -45.60 M USD, representing a -12.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Embecta since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Embecta

All Key Metrics — Embecta